What are Monoclonal Antibodies? A Complete Guide to mAbs

Before diving into modern medical treatments, it helps to look at the body’s natural defense system. Antibodies are specialized proteins that protect you when an unwanted substance enters your body. Produced naturally by your immune system, these proteins bind to unwanted foreign substances to eliminate them from your system. In scientific circles, another common word for an antibody is an immunoglobulin.

1. What are Monoclonal Antibodies (mAbs)?

Monoclonal antibodies (mAbs) are laboratory-engineered or plant-produced proteins designed to act in place of the antibodies naturally produced by the human body. They are called “monoclonal” because they are single clones—exact genetic copies—of a specific antibody that targets a single antigen.

By mimicking the immune system’s natural ability, mAbs precisely target specific antigens like cancer cells, viruses, or problematic inflammatory proteins without damaging surrounding tissue.

2. Structure and Architecture of Monoclonal Antibodies

Monoclonal antibodies belong to the Immunoglobulin (Ig) family. They share a classic, common Y-shaped structure built from four polypeptide chains:

Two identical heavy (H) chains: Longer chains containing more constant domains.
Two identical light (L) chains: Shorter structural chains.

These chains are bound securely together by disulfide bonds. Each individual chain contains variable (V) and constant (C) regions that balance antigen specificity with structural stability.

Key Functional Regions

Fab Region (Fragment, antigen-binding): Composed of the variable domain and the first constant domains of the heavy and light chains. This area handles direct antigen recognition through hypervariable loops called complementary determining regions (CDRs).
Fc Region (Fragment, crystallizable): Made up of the remaining constant domains of the heavy chains. It acts as the communicator, triggering effector functions by binding to Fc receptors on immune cells and activating the complement system.
Hinge Region: A highly flexible middle segment connecting the Fab and Fc regions. It allows the arms of the antibody to pivot freely, enhancing its ability to bind antigens at various angles.

Structural Summary

Variable domains (VH and VL): Dictate precise antigen specificity.
Constant domains (CH1, CH2, CH3, CL): Maintain structural stability and guide interactions with the immune system.
Formats: Available as Full-length IgG (classic therapeutic Y-shape) or engineered Fragment antibodies (Fab, F(ab’)2, scFv) used frequently in research.

3. A Brief History of Monoclonal Antibodies

The journey from a laboratory concept to a dominant class of pharmaceutical drugs was rapid:

1975: Scientists Köhler and Milstein invent the ground-breaking Hybridoma Technique.
1986: Muromonab-CD3 breaks barriers to become the very first FDA-approved therapeutic mAb.
Today: Well over 100 mAbs are approved globally, representing 7 of the world’s top-10 best-selling drugs.

4. The Major Types of Monoclonal Antibodies (mAbs)

Modern medicine classifies therapeutic mAbs into five primary functional categories based on how they work and what payload they carry:

Naked Monoclonal Antibodies

These are standalone proteins with no drugs, toxins, or radioactive isotopes attached. They are the most common therapeutic antibody type. Naked mAbs bind to target antigens to block checkpoint pathways, halt growth signals, or flag target cells for destruction via antibody-dependent cellular cytotoxicity (ADCC).

Trastuzumab (Herceptin): Blocks HER2 receptors in breast cancer to halt rapid cell growth.
Rituximab (Rituxan): Binds to CD20 on B-cells, marking them for destruction in lymphoma.
Pembrolizumab (Keytruda): Blocks the PD-1 pathway to unleash the body’s T-cells against hidden tumors.

Conjugated Monoclonal Antibodies (ADCs)

Commonly called Antibody-Drug Conjugates (ADCs), these molecules are chemically linked to a potent cytotoxic drug payload. The antibody acts as a homing missile to navigate the bloodstream and bind to a specific cell. Once bound, the cell swallows the complex, lysosomal enzymes cleave the stable chemical linker, and the payload destroys the target cell from within.

Trastuzumab deruxtecan (Enhertu): Delivers a topoisomerase I inhibitor directly into HER2-positive cancer cells.
Brentuximab vedotin (Adcetris): Delivers a targeted anti-mitotic agent to CD30-expressing lymphoma cells.

Radiolabeled Antibodies (Radioimmunotherapy)

These mAbs are chemically bound to a radioactive isotope payload. Instead of needing the cell to swallow the antibody, the attached radioisotope continuously emits ionizing radiation (alpha or beta particles) that damages the target cell’s DNA. It also provides a helpful “bystander effect,” destroying nearby tumor cells that the antibody might not have reached directly.

Ibritumomab tiuxetan (Zevalin): Utilizes Yttrium-90 to target CD20 receptors in non-Hodgkin’s lymphoma.
Pluvicto:Advanced radioligand therapy utilizing Lutetium-177 for targeted prostate cancer treatment.

Advanced Types of Monoclonal Antibodies (mAbs)

4. Chemolabeled Antibodies

Chemolabeled antibodies represent a highly specialized subclass of Antibody-Drug Conjugates (ADCs). These complex molecules consist of powerful chemotherapy agents or other highly toxic payloads chemically linked directly to the antibody frame. The attached drug is often far too toxic to be safely administered throughout the human body on its own without the strict, direct targeting provided by the antibody missile.

Brentuximab vedotin: Targets the CD30 surface antigen, chemically attached to the anti-mitotic payload MMAE. It is clinically utilized to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Ado-trastuzumab emtansine (TDM-1): Targets the HER2 receptor protein, chemically bound to the toxic agent DM1. It is frequently prescribed for HER2-positive breast cancer treatment.

5. Bispecific Monoclonal Antibodies

Unlike classic structural formats, bispecific monoclonal antibodies are engineered out of structural components from two entirely different mAbs. This unique modification allows them to bind to two distinct proteins or tissue cell types simultaneously.

Blinatumomab: Used clinically to treat acute lymphocytic leukemia (ALL). One specific part of the engineered molecule attaches directly to the CD19 antigen on target leukemia/lymphoma cells, while the opposing part secures the CD3 receptor on therapeutic T-cells—physically anchoring the body’s immune cells directly to the target cancer cells for immediate destruction.

Design & Source Sequence Classification

The host origin sequence used during engineering dictates how well a patient tolerates a therapeutic antibody. They are divided into four primary source classifications:

A. Murine Source mAbs: Derived completely from rodent protein sequences. While they offer incredibly high binding affinity and clear specificity, their clinical longevity is severely limited by the rapid development of a HAMA (Human Anti-Murine Antibody) immune rejection response.
B. Chimeric mAbs: Artificially combines human constant regions with rodent variable domains (retaining approximately 30% murine sequences). Though cleaner than pure rodent models, they still run a risk of triggering a HACA (Human Anti-Chimeric Antibody) immune response.
C. Humanized mAbs: Engineered by taking only the rodent CDR loops and grafting them seamlessly onto human framework regions. This results in a molecule that is roughly 95% human, drastically minimizing immunogenicity concerns.
D. Fully Human Antibodies: Advanced therapeutic proteins designed with 100% human protein sequences. Because they carry no animal-derived markers, they display exceptionally low immunogenicity, superior patient tolerance, and premium target specificity.

Monoclonal Antibody Nomenclature: Cracking the Naming Code

The global pharmaceutical industry follows a systematic structural naming code for monoclonal antibodies. By breaking down the components of an international nonproprietary name, you can immediately identify the drug’s origin and target:

1. The Universal Suffix

Every single registered monoclonal antibody drug name will always end with the strict suffix “-mab”.

2. The Origin Sub-Stem

The letters immediately preceding the suffix identify the structural composition source and class percentage:

Sub-Stem Code	Design Origin Reference	Clinical Drug Example
-u-	Fully Human (100% human sequence)	Panitumumab
-zu-	Humanized (~95% human sequence)	Trastzumab
-xi-	Chimeric (~65%–70% human sequence)	Ritximab
-o- / -a- / -e- / -i-	Animal Derived (Mouse, Rat, Hamster, or Primate)	Tositomumab

3. The Target Prefix Sub-Stem

Located right before the origin sub-stem, this code identifies the bodily system or disease mechanism the antibody is designed to navigate toward:

-tu(m)- Indicates general tumor targeting. This is further refined into specific disease areas such as -ma(r)- for breast tissue or tumors, -pr(o)- for prostate targets, and -co(l)- for colorectal system cancers.
-ci(r)- Indicates target orientation toward the cardiovascular or circulatory system (e.g., Bevacizumab).

Read More: